Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes
作者:Bin Wang、Zongyu Cai、Huixin Yao、Shixuan Jiao、Siliang Chen、Zhongcheng Yang、Wanqiu Huang、Qiang Ren、Zhijun Cao、Ya Chen、Luyong Zhang、Zheng Li
DOI:10.1016/j.ejmech.2022.114883
日期:2023.1
Type 2 diabetes mellitus (T2DM) is a lifelong disease that requires long-term medication to control glucose levels, and thereby long-acting drug has been clinically needed for improving medical adherence. The free fatty acid receptor 1 (FFA1) was considered as a promising target for several diseases, such as T2DM, pain and fatty liver. However, no once-weekly FFA1 agonist has been reported until now
2型糖尿病(T2DM)是一种终生性疾病,需要长期服药来控制血糖水平,因此临床上需要长效药物来提高医疗依从性。游离脂肪酸受体 1 (FFA1) 被认为是治疗多种疾病(如 T2DM、疼痛和脂肪肝)的有希望的靶标。然而,直到现在还没有报道过每周一次的 FFA1 激动剂。在此,我们报告了 ZLY50 的成功发现,这是第一个每周一次的 FFA1 激动剂,具有全新的化学类型、高度激动活性和对 FFA1 的选择性。此外,ZLY50 有足够的脑暴露来激活脑中的 FFA1,它是第一个具有镇痛活性的口服 FFA1 激动剂。值得注意的是,ZLY50(每周一次)的长期抗糖尿病和抗脂肪肝作用优于 HWL-088(每日一次),一种高效的 FFA1 激动剂,具有比 3 期临床候选药物 TAK-875 更强的降糖作用。进一步的机制研究表明,ZLY50通过调节肝脏脂质代谢、线粒体功能和氧化应激相关基因的表达来减轻脂肪肝。